ANADIN EXTRA

Main information

  • Trade name:
  • ANADIN EXTRA
  • Dosage:
  • 300/200/45 Milligram
  • Pharmaceutical form:
  • Film Coated Tablet
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ANADIN EXTRA
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0172/018/001
  • Authorization date:
  • 28-02-1984
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

AnadinExtraFilm-coatedTablets

Aspirin300mg

Paracetamol200mg

Caffeine45mg

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Filmcoatedtablet(tablet)

Acapsule-shapedwhitetabletwithabreakbarononesideandwith“A”and“E”debossedontheotherside.

Thescorelineistoallowbreakingforeaseofswallowing.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Forthereliefofpainof:

Headache.

Neuralgia.

Myalgia.

Rheumatism.

Toothache.

Dysmenorrhoea.

Symptomsofthecommoncoldorinfluenza.

4.2Posologyandmethodofadministration

AdultsandAdolescentsover16years:

1-2tabletsevery4hourswithamaximumof6inany24hourperiod.

Donotgivetochildrenandadolescentsagedunder16years,exceptonmedicaladvice,wherethebenefitoutweighs

therisk.

TheElderly:

Dosageisasabove.

Activeingredients mg/tablet

Acetylsalicylicacid 300.0mg

Paracetamol 200.0mg

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 16/04/2012 CRN 2112773 page number: 1

toadverseevents.Thelowestdosecompatiblewithadequatesafeclinicalcontrolshouldbeemployed.

Seealsosection4.4.

Treatmentshouldbereviewedatregularintervalsanddiscontinuedifnobenefitisseenorintoleranceoccurs.

4.3Contraindications

Hypersensitivitytotheactiveingredientsoranyotherconstituents.Patientswithahistoryofhypersensitivity

reactions(e.g.bronchospasm,rhinitis,urticaria)inresponsetoAnadinExtra,aspirinorothernon-steroidalanti-

inflammatorydrugsoranyoftheotherconstituents.

Bleedingdisorders,concurrentanti-coagulanttherapy.

Children,adolescentsunder16yearsandwhenbreastfeedingbecauseofpossibleriskofReye’sSyndrome(see

section4.6).

Historyofgastrointestinalbleedingorperforation,relatedtopreviousNSAIDstherapy.

Activeorhistoryofrecurrentpepticulcer/haemorrhage(twoormoredistinctepisodesofprovenulcerationor

bleeding).

Patientswithsevereheartfailure.

4.4Specialwarningsandprecautionsforuse

TheuseofAnadinExtraTabletswithconcomitantNSAIDsincludingcyclooxygenase-2selectiveinhibitorsshould

beavoided.

Undesirableeffectsmaybeminimizedbyusingtheminimumeffectivedosefortheshortestdurationnecessaryto

controlsymptoms.

Elderly:TheelderlyhaveanincreasedfrequencyofadversereactionstoNSAIDsespeciallygastrointestinal

bleedingandperforationwhichmaybefatal(seesection4.2).

Gastrointestinalbleeding,ulcerationandperforation:GIbleeding,ulcerationorperforation,whichcanbefatal,has

beenreportedwithallNSAIDsatanytimeduringtreatment,withorwithoutwarningsymptomsoraprevious

historyofseriousGIevents.

TheriskofGIbleeding,ulcerationorperforationishigherwithincreasingNSAIDdoses,inpatientswithahistory

ofulcer,particularlyifcomplicatedwithhaemorrhageorperforation(seesection4.3),andintheelderly.These

patientsshouldcommencetreatmentonthelowestdoseavailable.Combinationtherapywithprotectiveagents(e.g.

misoprostolorprotonpumpinhibitors)shouldbeconsideredforthesepatientsandalsoforpatientsrequiring

concomitantlowdoseaspirinorotherdrugslikelytoincreasegastrointestinalrisk(seebelowand4.5).

PatientswithahistoryofGItoxicity,particularlywhenelderly,shouldreportanyunusualabdominalsymptoms

(especiallyGIbleeding)particularlyintheinitialstagesoftreatment.

Cautionshouldbeadvisedinpatientsreceivingconcomitantmedicationwhichcouldincreasetheriskofulceration

orbleedingsuchasoralcorticosteroids,anticoagulantssuchaswarfarin,selectiveserotonin-reuptakeinhibitorsor

anti-plateletagentssuchasaspirin(seesection4.5).

WhenGIbleedingorulcerationoccursinpatientsreceivingAnadinExtraTablets,thetreatmentshouldbe

withdrawn.

NSAIDsshouldbegivenwithcaretopatientswithahistoryofgastrointestinaldisease(ulcerativecolitis,Crohn’s

disease)astheirconditionmaybeexacerbated(seesection4.8–undesirableeffects).

Patientswithahistoryofinflammatoryboweldisease,coagulationdisorders,asthmaorallergicdiseaseshould

consultadoctorbeforeusingthisproduct.

Aspirinmayinduceasthmaticattacksinhypersensitivepatients.

ThereisapossibleassociationbetweenaspirinandReye’ssyndromewhengiventochildren.Reyes’s

syndromeisaveryraredisease,whichaffectsthebrainandliverandcanbefatal.Forthisreason,aspirin

shouldnotbegiventochildrenandadolescentsagedunder16yearsunlessspecificallyindicated.

Prolongeduse,exceptundermedicalsupervision,canbeharmful.Ifsymptomspersist,thephysicianshouldbe

consulted.

Ifthepatientistakinganyothermedicationsorisunderthecareofadoctoryoushouldconsultthephysician

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 16/04/2012 CRN 2112773 page number: 2

Inpatientswithrenal,cardiacorhepaticimpairment,cautionisrequiredsincetheuseofNSAIDsmayresultin

deteriorationofrenalfunction.Assessmentofrenalfunctionshouldoccurpriortotheinitiationoftherapyand

regularlythereafter.

AsNSAIDscaninterferewithplateletfunction,theyshouldbeusedwithcautioninpatientswithintracranial

haemorrhageandbleedingdiathesis.

Thereissomeevidencethatdrugswhichinhibitcyclo-oxygenase/prostaglandinsynthesismaycause

impairmentoffemalefertilitybyaneffectonovulation.Thisisreversibleonwithdrawaloftreatment.

Cautionisrequiredinpatientswithahistoryofhypertensionand/orheartfailureasfluidretentionandoedema

havebeenreportedinassociationwithNSAIDtherapy.

Seriousskinreaction,someofthemfatal,includingexfoliativedermatitis,Stevens-Johnsonsyndromeand

toxicepidermalnecrolysis,havebeenreportedveryrarelyinassociationwiththeuseofNSAIDs(see4.8).

Patientsappeartobeathighestriskofthesereactionsearlyinthecourseoftherapy,theonsetofthereaction

occurringinthemajorityofcaseswithinthefirstmonthoftreatment.AnadinExtraTabletsshouldbe

discontinuedatthefirstappearanceofskinrash,mucosallesions,oranyothersignofhypersensitivity.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Aspirin

Careshouldbetakeninpatientstreatedwithanyofthefollowingdrugsasinteractionshavebeenreported:

Anti-coagulants: ItisconsideredunsafetotakeNSAIDsincombinationwithwarfarinorheparinunlessunder

directmedicalsupervisionasNSAIDsmayenhancetheeffectsofanti-coagulants.

Experimentaldatasuggestthatibuprofenmayinhibittheeffectoflowdoseaspirinonplateletaggregationwhentheyare

dosedconcomitantly.However,thelimitationsofthesedataandtheuncertaintiesregardingextrapolationofexvivodata

totheclinicalsituationimplythatnofirmconclusionscanbemadeforregularibuprofenuse,andnoclinicallyrelevant

effectisconsideredtobelikelyforoccasionalibuprofenuse(seesection5.1).

Anti-plateletagentsandselectiveserotoninreuptakeinhibitors(SSRIs):increasedriskofgastrointestinalbleeding(see

section4.4).

Anti-hypertensives: Reducedanti-hypertensiveeffect.

Diuretics: Reduceddiureticeffect.DiureticscanincreasetheriskofnephrotoxicityofNSAIDs.

Cardiacglycosides: NSAIDsmayexacerbatecardiacfailure,reduceGFRandincreaseplasmacardiacglycoside

levels.

Lithium: Decreasedeliminationoflithium.

Methotrexate: Decreasedeliminationofmethotrexate.

Cyclosporin: IncreasedriskofnephrotoxicitywithNSAIDs.

OtherNSAIDs: AvoidconcomitantuseoftwoormoreNSAIDs.

Corticosteroids: Increasedriskofgastrointestinalbleedingandulceration.

Aminoglycosides: Reductioninrenalfunctioninsusceptibleindividuals,decreasedeliminationof

aminoglycosideandincreasedplasmaconcentrations.

Probenecid: ReductioninmetabolismandeliminationofNSAIDandmetabolites.

Oralhypoglycemic

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 16/04/2012 CRN 2112773 page number: 3

hypoglycaemia.

Metoclopramide: Metoclopramideincreasestherateofabsorptionofaspirin.

However,concurrentuseneednotbeavoided.

Phenytoin: Theeffectofphenytoinmaybeenhancedbyaspirin.However,nospecialprecautionsare

needed.

Valproate: Theeffectofvalproatemaybeenhancedbyaspirin.

Paracetamol

Cholestyramine: Theabsorptionofparacetamolisreducedbycholestyramine.Thereforecholestyramine

shouldnotbetakenwithinonehourifmaximalanalgesiaisrequired.

Metoclopramide

andDomperidone: Theabsorptionofparacetamolisincreasedbymetoclopramideanddomperidone.

However,concurrentuseneednotbeavoided.

Warfarin: Potentiationofwarfarinwithcontinualhighdosageofparacetamol.

Chloramphenicol: Increasedplasmaconcentrationofchloramphenicol.

4.6Fertility,pregnancyandlactation

Aswithallotherdrugs,aspirinandparacetamolshouldbeusedduringpregnancyonlyafterstrictriskbenefit

evaluation.Thereisclinicalandepidemiologicalevidenceofsafetyofaspirininpregnancy,butitmayprolonglabour

andcontributetomaternalandneonatalbleeding,maycauseprematureclosureoftheductusarteriosusandsoshould

notbeusedinthelasttrimesterofpregnancy.

Aspirinappearsinbreastmilkandregularhighdosesmayaffectneonatalclotting.Notrecommendedwhilebreast

feedingduetopossibleriskofReye’sSyndromeaswellasneonatalbleedingduetohypoprothrombinaemia.

Thereisepidemiologicalevidenceofsafetyofparacetamolinhumanpregnancy.

Caffeineappearsinbreastmilk.Irritabilityandpoorsleepingpatternintheinfanthavebeenreported.

4.7Effectsonabilitytodriveandusemachines

Noneknown.

4.8Undesirableeffects

Themostcommonobservedadverseeventsaregastrointestinalinnature.Pepticulcers,perforationofGIbleeding,

sometiemsfatalintheelderly,mayoccur(seesection4.4).Nausea,vomiting,diarrhoea,flatulence,constipation,

dyspepsia,abdominalpain,melaena,haematemesis,ulcerativestomatitis,excerbationofcolitisandCrohn'sdisease

(seesection4.4-Specialwarningsandprecautionsforuse)havebeenreportedfollowingadministration.Less

frequently,gastritishasbeenobserved.Bronchospasm,rhinitisandskinreactionsinhypersensitivepatients.Aspirin

mayinducegastro-intestinalhaemorrhage,occasionallymajorwithsignssuchashaematemesisandmelena.Itmay

precipitategoutinsusceptibleindividuals.PossibleriskofReye’sSyndromeinchildrenunder16years.Isolated

reportsofthrombocytopenicpurpura,methaemoglobinaemiaandagranulocytosishaveoccurredafterparacetamoluse.

Inisolatedcases,followingprolongedadministrationoroverdose,chronichepaticnecrosis,acutepancreatitisand

nephrotoxicityhavebeenassociatedwithNSAIDuse.Suchsideeffectsarenotexpectedwhentheproductisusedas

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 16/04/2012 CRN 2112773 page number: 4

BullousreactionsincludingStevens-Johnsonsyndromandtoxicepidermalnecrolysis(veryrare).

Oedema,hypertensionandcardiacfailurehavebeenreportedinassociationwithNSAIDtreatment.

Highdosesofcaffeinecancausetremorandpalpitations.

4.9Overdose

Aspirin:

Severeintoxicationfromheavyoverdosageisshownbyhyperventilation,fever,restlessness,ketosis,respiratory

alkalosis,metabolicacidosisandconvulsions.Gastrointestinalhaemorrhageisfrequentinoverdose.

Paracetamol:

Immediatemedicaladviceshouldbesoughtintheeventofoverdosagebecauseoftheriskofirreversibleliverdamage.

Symptomsofparacetamoloverdosageinthefirst24hoursarepallor,nausea,vomiting,anorexiaandabdominalpain.

Liverdamagemaybecomeapparent12to48hoursafteringestionandthismaybemanifestedinincreasing

prothrombintime,whichisareliableindicatorofdeterioratingliverfunction.Abnormalitiesofglucosemetabolismand

metabolicacidosismayoccur.Inseverepoisoning,hepaticfailuremayprogresstoencephalopathy,comaanddeath.

Acuterenalfailurewithacutetubularnecrosismaydevelopevenintheabsenceofsevereliverdamage.Cardiac

arrhythmiasandpancreatitishavebeenreported.

Liverdamageislikelyinadultswhohavetaken10gormoreofparacetamolbuthasalsooccurredatdoseslowerthan

this.Itisconsideredthatexcessquantitiesoftoxicmetabolite(usuallyadequatelydetoxifiedbyglutathionewhen

normaldosesofparacetamolareingested),becomeirreversiblyboundtolivertissue.

Treatment

Aspirin:

Aworthwhilerecoveryofsalicylatescanbeachievedupto24hoursafteringestion.Treatmentmustbeinhospital

whereplasmasalicylatepHandelectrolytescanbemeasured.Fluidlossesarereplacedandforcedalkalinediuresisis

consideredwhentheplasmasalicylateconcentrationisgreaterthan500mg/litre(3.6mmol/litre)inadultsor

300mg/litre(2.2mmol/litre)inchildren.

Paracetamol:

Immediatetreatmentisessentialinthemanagementofparacetamoloverdose.Despitealackofsignificantearly

symptoms,patientsshouldbereferredtohospitalurgentlyforimmediatemedicalattention.Anypatientwhohas

ingestedaround7.5gormoreofparacetamolinthepreceding4hoursshouldundergogastriclavage.IntravenousN-

Acetylcysteineororalmethionineprotectstheliverifadministeredwithin8to12hoursofingestingtheoverdose.N-

Acetylcysteineiseffectiveuptoandpossiblybeyond24hours,butexpertadviceisessential.Generalsupportive

measuresmustbeavailable.

5PHARMACOLOGICALPROPERTIES

ATCcode:N02BA51

Pharmacotherapeuticgroup:Otheranalgesicsandantipyretics.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 16/04/2012 CRN 2112773 page number: 5

ASPIRIN

Mechanismsofactioneffect

Salicylatesinhibittheactivityoftheenzymecyclo-oxygenasetodecreasetheformationofprecursorsofprostaglandins

andthromboxanesfromarachidonicacid.Althoughmanyofthetherapeuticeffectsmayresultfrominhibitionof

prostaglandinsynthesis(andconsequentreductionofprostaglandinactivity)invarioustissues,otheractionsmayalso

contributesignificantlytothetherapeuticeffects.

Analgesic

Producesanalgesiathroughaperipheralactionbyblockingpainimpulsegenerationandviaacentralaction,possiblyin

thehypothalamus.

Anti-inflammatory(Nonsteroidal)

Exactmechanismshavenotbeendetermined.Salicylatesmayactperipherallyininflamedtissueprobablybyinhibiting

thesynthesisofprostaglandinsandpossiblybyinhibitingthesynthesisand/oractionsofothermediatorsofthe

inflammatoryresponse.

Antipyretic

Mayproduceantipyresisbyactingcentrallyonthehypothalamicheatregulatingcentretoproduceperipheral

vasodilationresultinginincreasedcutaneousbloodflow,sweatingandheatloss.

PARACETAMOL

Mechanismofaction/effect

Analgesic

Themechanismofanalgesicactionhasnotbeenfullydetermined.Paracetamolmayactpredominatelybyinhibiting

prostaglandinsynthesisinthecentralnervoussystem(CNS)and,toalesserextent,throughaperipheralactionby

blockingpainimpulsegeneration.

Theperipheralactionmayalsobeduetoinhibitionofprostaglandinsynthesisorinhibitionofthesynthesisoractions

ofothersubstancesthatsensitisepainreceptorstomechanicalorchemicalstimulations.

Antipyretic

Paracetamolprobablyproducesantipyresisbyactingcentrallyonthehypothalamicheat-regulationcentretoproduce

peripheralvasodilationresultinginincreasedbloodflowthroughtheskin,sweatingandheatloss.Thecentralaction

probablyinvolvesinhibitionofprostaglandinsynthesisinthehypothalamus.

CAFFEINE

Mechanismsofaction/effect

Centralnervoussystemstimulant

CaffeinestimulatesalllevelsoftheCNS,althoughitscorticaleffectsaremilderandofshorterdurationthatthoseof

amphetamines.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 16/04/2012 CRN 2112773 page number: 6

Caffeineconstrictscerebralvasculaturewithanaccompanyingdecreaseinthecerebralbloodflowandintheoxygen

tensionofthebrain.Itisbelievedthatcaffeinehelpstorelieveheadachebyprovidingmorerapidonsetofactionand/or

enhancedpainreliefwithlowerdosesofanalgesic.Recentstudieswithergotamineindicatethattheenhancementof

effectbytheadditionofcaffeinemayalsobeduetoimprovedgastrointestinalabsorptionofergotaminewhen

administeredwithcaffeine.

Experimentaldatasuggestthatibuprofenmayinhibittheeffectoflowdoseaspirinonplateletaggregationwhenthey

aredosedconcomitantly.Inonestudy,whenasingledoseofibuprofen400mgwastakenwithin8hbeforeorwithin

30minafterimmediatereleaseaspirindosing(81mg),adecreasedeffectofASAontheformationofthromboxaneor

plateletaggregationoccurred.However,thelimitationsofthesedataandtheuncertaintiesregardingextrapolationof

exvivodatatotheclinicalsituationimplythatnofirmconclusionscanbemadeforregularibuprofenuse,andno

clinicallyrelevanteffectisconsideredtobelikelyforoccasionalibuprofenuse.

5.2Pharmacokineticproperties

ASPIRIN

AbsorptionandFate

Absorptionisgenerallyrapidandcompletefollowingadministration.Itislargelyhydrolysedinthegastrointestinal

tract,liverandbloodtosalicylatewhichisfurthermetabolisedprimarilyintheliver.

PARACETAMOL

AbsorptionandFate

Paracetamolisreadilyabsorbedfromthegastro-intestinaltractwithpeakplasmaconcentrationsoccurringabout30

minutesto2hoursafteringestion.Itismetabolisedintheliverandexcretedintheurinemainlyastheglucuronideand

sulphateconjugates.Lessthen5%isexcretedasunchangedparacetamol.Theeliminationhalf-lifevariesfromabout1

to4hours.Plasma-proteinbindingisnegligibleatusualtherapeuticconcentrationsbutincreaseswithincreasing

concentrations.

Aminorhydroxylatedmetabolitewhichisusuallyproducedinverysmallamountsbymixed-functionoxidasesinthe

liverandwhichisusuallydetoxifiedbyconjugationwithliverglutathionemayaccumulatefollowingparacetamol

overdosageandcauseliverdamage.

CAFFEINE

AbsorptionandFate

Caffeineiscompletelyandrapidlyabsorbedafteroraladministrationwithpeakconcentrationsoccurringbetween5and

90minutesafterdoseinfastedsubjects.Thereisnoevidenceofpresystemicmetabolism.Eliminationisalmostentirely

byhepaticmetabolisminadults.

Inadults,markedindividualvariabilityintherateofeliminationoccurs.Themeanplasmaeliminationhalflifeis4.9

hourswitharangeof1.9-12.2hours.Caffeinedistributesintoallbodyfluids.Themeanplasmaproteinbindingof

caffeineis35%.

Caffeineismetabolisedalmostcompletelyviaoxidation,demethylation,andacetylationandisexcretedintheurine.

Themajormetabolitesare1-methylxanthine,7-methylxanthine,1,7-dimethylxanthine(paraxanthine).Minor

metabolitesinclude1-methyluricacidand5-acetylamino-6formylamion,3-methyluracil(AMFU).

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 16/04/2012 CRN 2112773 page number: 7

TheactiveingredientsinAnadinExtraTabletshaveawellestablishedsafetyrecord.Thiscombinationofingredients

hasbeenmarketedforanumberofyears.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Tabletcore:

Maizestarch

Microcrystallinecellulose

Hydrogenatedvegetableoil(Sterotex)

Pregelatinisedstarch

Povidone

Tabletcoat:

Hypromellose(MethocelE5)

Hypromellose(MethocelE15)

Macrogol(Carbowax3350)

6.2Incompatibilities

Notapplicable.

6.3Shelflife

3years

6.4Specialprecautionsforstorage

Donotstoreabove25 o

Storeintheoriginalpackage(toprotectfrommoisture).

6.5Natureandcontentsofcontainer

CartonscontaininguPVC/Aluminiumblisterstrip-6,8,12and24tablets.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 16/04/2012 CRN 2112773 page number: 8

7MARKETINGAUTHORISATIONHOLDER

PfizerConsumerHealthcareLtd

RamsgateRoad

Sandwich

Kent

CT139NJ

UnitedKingdom

8MARKETINGAUTHORISATIONNUMBER

PA172/18/1

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:28February1984

Dateoflastrenewal:28February2009

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 16/04/2012 CRN 2112773 page number: 9